NCT00950521

Efficacy Study of CD34 Stem Cell in Chronic Stroke Patients

Phase II Study of Autologous Peripheral Blood CD34 Stem Cell Implantation in Chronic Stroke Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: China Medical University Hospital · Academic / Other
• Sex: All
• Age: 35 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The objective of the study is to determine the efficacy of brain transplants of CD34+ stem cells obtained from peripheral blood of patients in the treatment of chronic stroke patients.

Detailed description

30 patients are divided into 2 groups, one treatment group and one control group.Treatment group will be implanted with peripheral blood stem cell and receive convention stroke therapy ,and control group only receive convention stroke therapy. We expect that transplantation of the peripheral blood CD34+ cells has the potential of significant benefit to neurological recovery. In a previous phase I clinical trial, we have shown that transplantation of CD34+ cells obtained from the peripheral blood of the chronic stroke patients was safe and beneficial for neurological recovery. We expect this trial can further prove the efficacy of this treatment method.

Conditions

• Stroke
• Middle Cerebral Artery Infarction

Interventions

Type	Name	Description
PROCEDURE	Intercerebral implantation of Autulogous Stem Cells	2-8 millions Stem cell per patients plus convention therapy
DRUG	convention therapy	antiplatelet

Timeline

• Start date: 2009-06-01
• Primary completion: 2010-12-01
• Completion: 2010-12-01
• First posted: 2009-07-31
• Last updated: 2011-04-21

Locations

1 site across 1 country: Taiwan